ArticleFrontiers in immunology2018
Factors Influencing the Differentiation of Human Monocytic Myeloid-Derived Suppressor Cells Into Inflammatory Macrophages.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Myeloid-derived suppressor cells in cancer: biology, regulatory networks and theranostic prospects.Signal transduction and targeted therapy · 2026Review
- Myeloid-Derived Suppressor Cells in Cancer: Metabolic Reprogramming, Immune Crosstalk, and Therapeutic Targeting.Cancers · 2026Review
- Divergent myeloid and lymphoid immune landscapes in HPV/p16 positive and HPV/p16 negative oropharyngeal squamous cell carcinomas and their lymph node metastases.Molecular medicine (Cambridge, Mass.) · 2026Article
- Dual Roles of CD147 in Regulating THP-1 Monocyte Migration and MCP-1-Induced Inflammatory Responses.International journal of molecular sciences · 2025Article
- Immunoregulatory iPSC-derived non-lymphoid progeny in autoimmunity and GVHD alloimmunity.Stem cells (Dayton, Ohio) · 2025Review
- DSP-0509, a TLR7 agonist, exerted synergistic anti-tumor immunity combined with various immune therapies through modulating diverse immune cells in cancer microenvironment.Frontiers in oncology · 2024Article
- Liquid nitrogen frozen cells for chemotherapy drug delivery and vaccination of melanoma.Journal of cancer research and clinical oncology · 2023Article
- UBC9 deficiency enhances immunostimulatory macrophage activation and subsequent antitumor T cell response in prostate cancer.The Journal of clinical investigation · 2023Article
- Antitumor efficacy of multi-targetJournal of biomedical research · 2022Article
- Circulating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes.Mechanisms of ageing and development · 2022Review
- Amelioration of systemic antitumor immune responses in cocktail therapy by immunomodulatory nanozymes.Science advances · 2022Article
- Deciphering the Molecular Signature of Human Hyalocytes in Relation to Other Innate Immune Cell Populations.Investigative ophthalmology & visual science · 2022Article
- The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis.Experientia supplementum (2012) · 2022Article
- In-Depth Molecular Profiling Specifies Human Retinal Microglia Identity.Frontiers in immunology · 2022Article
- Myeloid-derived suppressor cell (MDSC) key genes analysis in rat anti-CD28-induced immune tolerance kidney transplantation.Translational andrology and urology · 2021Article
- Active Microneedle Administration of Plant Virus Nanoparticles for CancerACS applied nano materials · 2020Article
- Neuroendocrine Modulation of the Immune Response after Trauma and Sepsis: Does It Influence Outcome?Journal of clinical medicine · 2020Review
- Androgen-Mediated Anti-inflammatory Cellular Processes as Therapeutic Targets in Lupus.Frontiers in immunology · 2020Review
- Transcriptional Profiling Uncovers Human Hyalocytes as a Unique Innate Immune Cell Population.Frontiers in immunology · 2020Article
- Energy metabolism manipulates the fate and function of tumour myeloid-derived suppressor cells.British journal of cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monocytic myeloid-derived suppressor cells (mMDSC) accumulate within tumors where they create an immunosuppressive milieu that inhibits the activity of cytotoxic T and NK cells thereby allowing cancers to evade immune elimination. The toll-like receptors 7/8 agonist R848 induces human mMDSC to mature into inflammatory macrophage (MAC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.